Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/2054358117698667 http://scihub22266oqcxt.onion/10.1177/2054358117698667 C5433659!5433659!28540057     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Can+J+Kidney+Health+Dis 2017 ; 4 (ä): ä Nephropedia Template TP {{tp|p=28540057|t=2017. Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies |pdf=|usr=}}{{28540057}} gab.com Text Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies JO: Can J Kidney Health Dis http://www.kidney.de/pget.php?&tw=1&pmid=28540057 #FOAvip Treatment with rituximab, a monoclonal antibody against the B-lymphocyte surface protein CD20, leads to the depletion of B cells. Recently, rituximab was reported to effectively prevent relapses of glucocorticoid-dependent or frequently relapsing minimal change disease (MCD). MCD is thought to be T-cell mediated; how rituximab controls MCD is not understood. In this review, we summarize key clinical studies demonstrating the efficacy of rituximab in idiopathic nephrotic syndrome, mainly MCD. We then discuss immunological features of this disease and potential mechanisms of action of rituximab in its treatment based on what is known about the therapeutic action of rituximab in other immune-mediated disorders. We believe that studies aimed at understanding the mechanisms of action of rituximab in MCD will provide a novel approach to resolve the elusive immune pathophysiology of MCD. Twit Text FOAVip Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies ????Can J Kidney Health Dis http://www.kidney.de/pget.php?&tw=1&pmid=28540057 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28540057 #FOAvip English Wikipedia <ref>{{Cite pmid|28540057}}</ref> Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies #MMPMID28540057 Madanchi N; Bitzan M; Takano T Can J Kidney Health Dis 2017[]; 4 (ä): ä PMID28540057show ga Treatment with rituximab, a monoclonal antibody against the B-lymphocyte surface protein CD20, leads to the depletion of B cells. Recently, rituximab was reported to effectively prevent relapses of glucocorticoid-dependent or frequently relapsing minimal change disease (MCD). MCD is thought to be T-cell mediated; how rituximab controls MCD is not understood. In this review, we summarize key clinical studies demonstrating the efficacy of rituximab in idiopathic nephrotic syndrome, mainly MCD. We then discuss immunological features of this disease and potential mechanisms of action of rituximab in its treatment based on what is known about the therapeutic action of rituximab in other immune-mediated disorders. We believe that studies aimed at understanding the mechanisms of action of rituximab in MCD will provide a novel approach to resolve the elusive immune pathophysiology of MCD. äRituximab in Minimal Change Disease: Mechanisms of Action and Hypothes(epmc).pdf DeepDyve Pubget Overpricing